Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans

Purnima P. Desai, Hugh Hendrie, Rebecca M. Evans, Jill R. Murrell, Steven T. DeKosky, M. Ilyas Kamboh

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Apolipoprotein D (APOD, gene; apoD, protein) is involved in neuroregenerative and neurodegenerative processes, and is upregulated in late-onset Alzheimer disease (AD) patients compared to nondemented controls. No genetic association studies have yet been carried out to investigate the role of APOD in AD. We have reported recently several sequence variants in the APOD gene, which are present exclusively among African blacks. In the present study we examined the role of four APOD genetic variants (Intron 1, codons 36, 108, 158) in modifying the risk of AD in 70 subjects with AD and 163 nondemented subjects from a population-based African-American cohort in Indianapolis. The Intron 1*2 allele was associated with an increased AD risk with an age, gender and APOE adjusted odds ratio (OR) of 2.29 (95% confidence interval [CI]: 1.19-4.43; P = 0.013), and this risk was confined to APOE*4 carriers (OR 3.12; 95% CI: 1.13-8.60; P=0.028). The frequency of the codon 36/GT genotype was non-significantly higher in individuals with AD than nondemented subjects (4.3% vs. 1.2%) with an adjusted OR of 4.24 (95% CI: 0.66-27.14; P = 0.13). Our data suggest that the risk of AD among African-Americans may be modified by genetic variation in APOD. Larger population-based or case-control studies are needed to confirm the role of APOD genetic variation in AD.

Original languageEnglish
Pages (from-to)98-101
Number of pages4
JournalAmerican Journal of Medical Genetics, Part B: Neuropsychiatric Genetics
Volume116 B
Issue number1
StatePublished - Jan 1 2003

Fingerprint

Apolipoproteins D
African Americans
Alzheimer Disease
Odds Ratio
Confidence Intervals
Codon
Introns
Genetic Association Studies
Population
Case-Control Studies
Alleles
Genotype

Keywords

  • AD
  • African-Americans
  • Alzheimer disease
  • APOD
  • Apolipoprotein D
  • Association study
  • Polymorphisms

ASJC Scopus subject areas

  • Genetics(clinical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)

Cite this

Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans. / Desai, Purnima P.; Hendrie, Hugh; Evans, Rebecca M.; Murrell, Jill R.; DeKosky, Steven T.; Kamboh, M. Ilyas.

In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 116 B, No. 1, 01.01.2003, p. 98-101.

Research output: Contribution to journalArticle

Desai, Purnima P. ; Hendrie, Hugh ; Evans, Rebecca M. ; Murrell, Jill R. ; DeKosky, Steven T. ; Kamboh, M. Ilyas. / Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans. In: American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics. 2003 ; Vol. 116 B, No. 1. pp. 98-101.
@article{4513f647ccaa4cb38627423b268475d3,
title = "Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans",
abstract = "Apolipoprotein D (APOD, gene; apoD, protein) is involved in neuroregenerative and neurodegenerative processes, and is upregulated in late-onset Alzheimer disease (AD) patients compared to nondemented controls. No genetic association studies have yet been carried out to investigate the role of APOD in AD. We have reported recently several sequence variants in the APOD gene, which are present exclusively among African blacks. In the present study we examined the role of four APOD genetic variants (Intron 1, codons 36, 108, 158) in modifying the risk of AD in 70 subjects with AD and 163 nondemented subjects from a population-based African-American cohort in Indianapolis. The Intron 1*2 allele was associated with an increased AD risk with an age, gender and APOE adjusted odds ratio (OR) of 2.29 (95{\%} confidence interval [CI]: 1.19-4.43; P = 0.013), and this risk was confined to APOE*4 carriers (OR 3.12; 95{\%} CI: 1.13-8.60; P=0.028). The frequency of the codon 36/GT genotype was non-significantly higher in individuals with AD than nondemented subjects (4.3{\%} vs. 1.2{\%}) with an adjusted OR of 4.24 (95{\%} CI: 0.66-27.14; P = 0.13). Our data suggest that the risk of AD among African-Americans may be modified by genetic variation in APOD. Larger population-based or case-control studies are needed to confirm the role of APOD genetic variation in AD.",
keywords = "AD, African-Americans, Alzheimer disease, APOD, Apolipoprotein D, Association study, Polymorphisms",
author = "Desai, {Purnima P.} and Hugh Hendrie and Evans, {Rebecca M.} and Murrell, {Jill R.} and DeKosky, {Steven T.} and Kamboh, {M. Ilyas}",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "116 B",
pages = "98--101",
journal = "American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics",
issn = "1552-4841",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in African-Americans

AU - Desai, Purnima P.

AU - Hendrie, Hugh

AU - Evans, Rebecca M.

AU - Murrell, Jill R.

AU - DeKosky, Steven T.

AU - Kamboh, M. Ilyas

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Apolipoprotein D (APOD, gene; apoD, protein) is involved in neuroregenerative and neurodegenerative processes, and is upregulated in late-onset Alzheimer disease (AD) patients compared to nondemented controls. No genetic association studies have yet been carried out to investigate the role of APOD in AD. We have reported recently several sequence variants in the APOD gene, which are present exclusively among African blacks. In the present study we examined the role of four APOD genetic variants (Intron 1, codons 36, 108, 158) in modifying the risk of AD in 70 subjects with AD and 163 nondemented subjects from a population-based African-American cohort in Indianapolis. The Intron 1*2 allele was associated with an increased AD risk with an age, gender and APOE adjusted odds ratio (OR) of 2.29 (95% confidence interval [CI]: 1.19-4.43; P = 0.013), and this risk was confined to APOE*4 carriers (OR 3.12; 95% CI: 1.13-8.60; P=0.028). The frequency of the codon 36/GT genotype was non-significantly higher in individuals with AD than nondemented subjects (4.3% vs. 1.2%) with an adjusted OR of 4.24 (95% CI: 0.66-27.14; P = 0.13). Our data suggest that the risk of AD among African-Americans may be modified by genetic variation in APOD. Larger population-based or case-control studies are needed to confirm the role of APOD genetic variation in AD.

AB - Apolipoprotein D (APOD, gene; apoD, protein) is involved in neuroregenerative and neurodegenerative processes, and is upregulated in late-onset Alzheimer disease (AD) patients compared to nondemented controls. No genetic association studies have yet been carried out to investigate the role of APOD in AD. We have reported recently several sequence variants in the APOD gene, which are present exclusively among African blacks. In the present study we examined the role of four APOD genetic variants (Intron 1, codons 36, 108, 158) in modifying the risk of AD in 70 subjects with AD and 163 nondemented subjects from a population-based African-American cohort in Indianapolis. The Intron 1*2 allele was associated with an increased AD risk with an age, gender and APOE adjusted odds ratio (OR) of 2.29 (95% confidence interval [CI]: 1.19-4.43; P = 0.013), and this risk was confined to APOE*4 carriers (OR 3.12; 95% CI: 1.13-8.60; P=0.028). The frequency of the codon 36/GT genotype was non-significantly higher in individuals with AD than nondemented subjects (4.3% vs. 1.2%) with an adjusted OR of 4.24 (95% CI: 0.66-27.14; P = 0.13). Our data suggest that the risk of AD among African-Americans may be modified by genetic variation in APOD. Larger population-based or case-control studies are needed to confirm the role of APOD genetic variation in AD.

KW - AD

KW - African-Americans

KW - Alzheimer disease

KW - APOD

KW - Apolipoprotein D

KW - Association study

KW - Polymorphisms

UR - http://www.scopus.com/inward/record.url?scp=0042326231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042326231&partnerID=8YFLogxK

M3 - Article

VL - 116 B

SP - 98

EP - 101

JO - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

JF - American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics

SN - 1552-4841

IS - 1

ER -